Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (531-540 of 842) with videos related to

Pageof 85
Sort By:
The New England Journal of Medicine|November 12, 1992
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation InvestigatorsM D Ezekowitz, S L Bridgers, K E James, et al.
Journal of the American Heart Association|January 18, 2019
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY TrialZiad Hijazi, Paolo Verdecchia, Jonas Oldgren, et al.
European Journal of Heart Failure|January 28, 2014
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF TrialMustafa Toma, Justin A Ezekowitz, Jeffrey A Bakal, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Heart Failure|October 4, 2012
Acute heart failure: perspectives from a randomized trial and a simultaneous registryJustin A Ezekowitz, Jia Hu, Diego Delgado, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
European Journal of Heart Failure|June 16, 2023
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure RegistryNgoc V Nguyen, Felix Lindberg, Lina Benson, et al.
American Heart Journal|June 5, 2017
Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk scoreIsmail R Raslan, Paul Brown, Cynthia M Westerhout, et al.
Pharmacogenomics|August 5, 2016
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudyNiclas Eriksson, Lars Wallentin, Lars Berglund, et al.
European Journal of Heart Failure|January 29, 2016
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trialsYee Weng Wong, Robert J Mentz, G Michael Felker, et al.
Pageof 85

Showing results (531-540 of 842) with videos related to

Sort By:
Pageof 85
The New England Journal of Medicine|November 12, 1992
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation InvestigatorsM D Ezekowitz, S L Bridgers, K E James, et al.
Journal of the American Heart Association|January 18, 2019
Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY TrialZiad Hijazi, Paolo Verdecchia, Jonas Oldgren, et al.
European Journal of Heart Failure|January 28, 2014
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF TrialMustafa Toma, Justin A Ezekowitz, Jeffrey A Bakal, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Circulation. Heart Failure|October 4, 2012
Acute heart failure: perspectives from a randomized trial and a simultaneous registryJustin A Ezekowitz, Jia Hu, Diego Delgado, et al.
Circulation. Cardiovascular Quality and Outcomes|March 25, 2024
Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized TrialsSachin J Shah, Carl van Walraven, Sun Young Jeon, et al.
European Journal of Heart Failure|June 16, 2023
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure RegistryNgoc V Nguyen, Felix Lindberg, Lina Benson, et al.
American Heart Journal|June 5, 2017
Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk scoreIsmail R Raslan, Paul Brown, Cynthia M Westerhout, et al.
Pharmacogenomics|August 5, 2016
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudyNiclas Eriksson, Lars Wallentin, Lars Berglund, et al.
European Journal of Heart Failure|January 29, 2016
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trialsYee Weng Wong, Robert J Mentz, G Michael Felker, et al.
Pageof 85